Background Pheochromocytomas (PCCs) develop from the adrenal medulla and are often part of a hereditary syndrome such as von Hippel-Lindau (VHL) syndrome. In VHL, only about 30 % of patients with a VHL missense mutation develop PCCs. Thus, additional genetic events leading to formation of such tumors in patients with VHL syndrome are sought. SDHAF2 (previously termed SDH5) and SDHD are both located on chromosome 11q and are required for the function of mitochondrial complex II. While SDHAF2 has been shown to be mutated in patients with paragangliomas (PGLs), SDHD mutations have been found both in patients with PCCs and in patients with PGLs.
Materials and methods Because loss of 11q is a common event in VHL-associated PCCs, we aimed to investigate whether SDHAF2 and SDHD are targets. In the present study, 41 VHL-associated PCCs were screened for mutations and loss of heterozygosity (LOH) in SDHAF2 or SDHD. Promoter methylation, as well as mRNA expression of SDHAF2 and SDHD, was studied. In addition, immunohistochemistry (IHC) of SDHB, known to be a universal marker for loss of any part the SDH complex, was conducted. Results and conclusions LOH was found in more than 50 % of the VHL-associated PCCs, and was correlated with a significant decrease (p \ 0.05) in both SDHAF2 and SDHD mRNA expression, which may be suggestive of a pathogenic role. However, while SDHB protein expression as determined by IHC in a small cohort of tumors was lower in PCCs than in the surrounding adrenal cortex, there Johan Kugelberg and Jenny Welander contributed equally to this work.
Introduction
Pheochromocytomas (PCCs), also termed adrenal paragangliomas (PGLs), are tumors derived from chromaffin cells in the adrenal medulla while PGLs develop from neural crest-derived paraganglia of the autonomic nervous system and can be found throughout the body, from the pelvis to the head and neck [1] . They frequently cause hypertension due to excessive catecholamine production and secretion. With the current data related to discoveries of new genes in the pathogenesis of PCCs and PGLs, the proportion of hereditary tumors is estimated to be around 30-35 % [2] [3] [4] . The vast majority of affected patients belong to one of the following syndromes: von HippelLindau (VHL) [5] , multiple endocrine neoplasia type 2 (MEN 2) [6] , von Recklinghausen (NF1) [7] , or PCC-PGL syndrome (PGL types 1-4) [8] [9] [10] [11] , which are caused by germline mutations in VHL, RET, NF1, and SDHx (SDHA, SDHB, SDHC, SDHD, and SDHAF2/SDH5), respectively. In addition, germline mutations in KIF1Bb have been found in patients with PCCs, neuroblastomas, and other neural and non-neural tumors [12, 13] . More recently, EPAS1/HIF2A germline mutations were found in patients with PCCs/PGLs and polycythemia (polycythemia-PGL syndrome) [14] . Susceptibility genes for which no syndromic form has yet been described include EGLN1 [15] , TMEM127 [16] , and MAX [17] .
The majority of patients with VHL-associated PCCs have missense VHL germline mutations [18] . While probably \1 % of patients with nonsense, microdeletion/ insertion, or deletion germline mutations of VHL develop PCCs, about 30 % of patients with missense germline mutations do so. Because only a subset of patients with missense VHL germline mutations develop PCCs, additional genetic events contributing to the formation of such tumors are sought after. Loss involving the long arm of chromosome 11 (11q) has been reported in almost 70 % of VHL-associated PCCs [19] , but no specific additional PCC triggering gene has yet been identified.
The SDH complex (mitochondrial complex II) plays an important role in the electron transport chain and the Krebs cycle [20] . SDHAF2 (succinate dehydrogenase complex assembly factor 2), a gene located on chromosome 11q12.2, encodes a protein that interacts with the catalytic subunit of the SDH complex and is required for SDHdependent respiration. SDHAF2 was shown to act as a tumor suppressor [21] , and mutations in the gene were detected in unrelated families with hereditary PGLs [21, 22] . SDHD (succinate dehydrogenase complex, subunit D, integral membrane protein) is located on chromosomal region 11q23. The gene encodes a protein forming one of two transmembrane subunits in the SDH complex, important for the function of the electron transport chain [20] .
This study investigates whether SDHAF2 and/or SDHD are targets of additional altering events within 11q that could promote PCC development in carriers of VHL germline mutation. A panel of VHL-associated PCCs was screened for mutations and loss of heterozygosity (LOH) in SDHAF2 and SDHD. Promoter methylation was investigated as an alternative mechanism of gene inactivation, and levels of mRNA expression of SDHAF2 and SDHD were analyzed in tumors with and without LOH. Finally, protein expression studies were conducted by staining for the SDHB protein since it is considered a universal marker for loss of any of the SDH subunits [23] .
Materials and methods

Patients and samples
Forty-one PCCs from 40 patients with a VHL missense germline mutation were studied. For 19 of these tumors, paired blood samples were available for LOH analysis. The samples were obtained through the University of Freiburg, Germany, the University of Padova, Italy, and the University of Texas Health Science Center, USA. Tumor and blood samples were snap frozen in liquid nitrogen and stored at B-70°C, or in some cases stored in RNAlater (Ambion, Austin, TX, USA). DNA was isolated using TRIzol (Invitrogen, Paisley, UK) or previously published methods [19] , and RNA was isolated using TRIzol (Invitrogen). Informed consent was given in all cases and the local ethic committees approved the study.
LOH analysis by microsatellite genotyping
Tumor and blood samples were genotyped for microsatellite markers D11S4191, D11S1765, D11S4076, and D11S1883, which are all in close proximity to SDHAF2, as well as D11S1793, D11S1986, D11S897, D11S3179 in close proximity to SDHD (Table 1) .
For each marker, 50 ng of DNA was amplified for 35 cycles using HotStar Taq Polymerase (Qiagen, Hilden, Germany) with primers and annealing temperatures as specified in Table 1 . Forward primers were labeled with 6-FAM fluorophore (Sigma-Aldrich, St. Louis, MO, USA). Amplicons were denatured at 95°C and separated by World J Surg (2014) 38:724-732 725 capillary electrophoresis on a 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 600-LIZ (Applied Biosystems) was used as a size standard, and results were analyzed with GeneMapper v. 4.0 (Applied Biosystems). Tumors were regarded as positive for LOH when the mean allele ratio between tumor and blood, calculated as earlier described [24] , was \0.7 for all informative markers, and apparent differences between tumor and blood allele ratios were seen in the electropherograms. In cases where no blood was available, allele peak ratios were compared to blood samples with the same or very similar allele combinations, followed by careful visual inspection of the electropherograms. Obvious allelic imbalance, i.e., large differences in allele peak heights and/ or a higher peak in the longest allele were regarded as indicative of loss. Cases inconclusive at visual inspection and/or with one or more allele ratios [0.7 but \0.8 were regarded as inconclusive for LOH.
DNA sequencing SDHAF2 and SDHD both contain 4 exons and 3 introns. Primers were designed to amplify exons 1-4 for each gene, including the 5 0 -and 3 0 -untranslated regions (Table 2) . For each exon, 50 ng of tumor DNA was PCR-amplified for 35 cycles using Thermo White Taq DNA Polymerase (Saveen Werner, Limhamn, Sweden) at annealing temperatures as specified in Table 2 . Polymerase chain reaction (PCR) products were purified from unconsumed primers and dNTPs with ExoSAP-IT (GE Healthcare, Waukesha, WI, USA), and Sanger sequencing was performed by a dideoxynucleotide chain termination reaction using BigDye Terminator 1.1 (Applied Biosystems) and the above primers. Separation was performed by capillary electrophoresis on a 3500 Genetic Analyzer (Applied Biosystems). Sequences were analyzed by alignment to the Ensembl sequence in NCBI BLAST, as well as by visual inspection in Sequence Scanner v 1.0 (Applied Biosystems).
Methylation-specific PCR
Promoter methylation was studied by methylation-specific PCR [25] , using primers specific for the unmethylated (U) and methylated (M) sequence in the SDHAF2 and SDHD gene promoters using previously described methodology [26] . Bisulfate conversion of 400 ng of tumor DNA was performed with the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). In each PCR (U and M), 1 ll of product was used, with the HotStar Taq . The PCR products were separated in 1.5 % agarose gels containing ethidium bromide, and they were then visualized with UV light. Methylated, unmethylated, and non-converted wild-type DNA from the EpitTect PCR Control DNA Set (Qiagen) was used as the control. Bisulfite-converted blood-DNA samples from four patients were also included as controls. The gene HIC1 (hypermethylated in cancer 1), which has previously been shown to be hypermethylated in VHLassociated PCCs [27] , was analyzed as a control, using methylation-specific PCR with previously published primers [28] .
Quantitative mRNA expression analysis Expressions of SDHAF2 and SDHD mRNA were investigated by reverse transcription quantitative real time PCR (RT-qPCR) in those tumors for which RNA was available. RNA integrity was validated by microfluidic analysis on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 500 ng of total RNA was transcribed into cDNA with a Maxima First Strand cDNA Synthesis kit (Thermo Scientific, Waltham, MA, USA). Gene expression was measured on the 7900HT Fast Real-Time PCR System (Applied Biosystems), using pre-designed primer-probe mixes covering exon boundaries [26] and the TaqMan Fast Universal PCR Master mix (Applied Biosystems). GUSB and HPRT1 (Applied Biosystems) were used as reference genes and were analyzed simultaneously with SDHAF2 and SDHD for all samples. These reference genes were selected because they have shown stable expression in several tumor forms [29] and had expression levels comparable to SDHAF2 and SDHD in our samples. cDNA transcribed from 20 ng of total RNA was used in each reaction, and all reactions were performed in triplicate. Normalized relative expressions of SDHAF2 and SDHD were calculated according to established methods [30] as follows: mean threshold cycle (C T ) value was calculated for each sample and gene by taking the mean of the PCR replicates. A normalized value (DC T ) was calculated by subtracting the mean of C T (GUSB) and C T (HPRT1) from C T (SDHAF2) , and finally the relative expression was obtained as 2 -DCT .
Immunohistochemistry
Immunohistochemistry was performed on 4-5-lm-thick formalin-fixed and paraffin-embedded sections from each tumor sample in an automated system (Bond-maX, Menarini, Florence, Italy) according to the recommendations of the manufacturer. Anti-SDHB (mouse monoclonal, clone 21A11, Abcam, Cambridge, UK; dilution 1:1200, EDTA 30 min) was used as primary antibody. Sections were then lightly counterstained with hematoxylin. Appropriate 
Results
Frequent LOH at SDHAF2 and SDHD
From 41 investigated VHL-associated PCCs, LOH or allelic imbalance indicative of LOH were identified in 22
(54 %) and 21 (51 %) tumors for SDHAF2 (Fig. 1a, b) and SDHD, respectively (Fig. 1c, d ). Concerning SDHAF2, another three tumors (7 %) showed signs of LOH, but this could not be fully determined (one or more allele ratios [0.7 but \0.8 and/or inconclusive at visual inspection). Regarding SDHD, this applied to 8 (20 %) tumors. Normal heterozygosity with no signs of LOH (allele ratios between 0.9 and 1.0 and/or no signs of loss in electropherograms) for SDHAF2 was found in 16 (39 %) tumors. Concerning SDHD, 12 (29 %) tumors showed normal heterozygosity. . Allele ratios were calculated as previously described [24] . The ratio between tumor and normal allele ratios, i.e., T1:T2/N1:N2, where T1 and N1 are the peak heights of the shorter allele in the tumor and normal sample, respectively, and T2 and N2 are the peak heights of the longer allele. In cases where the ratio was [1, it was converted using 1/(T1:T2/N1:N2)
Screening for SDHAF2A and SDHD mutations
No SDHAF2A or SDHD mutations were identified by direct sequencing in 39 informative PCCs. A common polymorphism (rs17702, C ? T) in the 3 0 UTR region of exon 4 was detected in heterozygous form in 6 tumors (15 %) and, where available, the corresponding blood samples displayed the same genotype as the tumors. In tumors with LOH, the peak size of one of the alleles was clearly reduced and sometimes hardly distinguishable. Allele frequencies of rs17702 did not differ significantly between the patients and 113 HapMap-CEU individuals reported at Ensembl (p = 0.12, two-tailed Fisher's exact test).
Promoter methylation analyses
Methylation-specific PCR for SDHAF2 and SDHD investigated in 27 PCC samples showed no promoter methylation. All samples yielded PCR products when primers specific for unmethylated DNA were used but not when methylation-specific primers were used (Fig. 2) . In order to study the methylation status of our samples, the gene HIC1 was used as a control in methylation-specific PCR. HIC1 was found to be methylated in all tumor samples (Fig. 2) but not in any of the tested blood samples.
Reduced SDHAF2 and SDHD expression
The mean relative SDHAF2 mRNA expression (2 -DCT ), normalized against the reference genes GUSB and HPRT1, was 2.2 times lower in tumors with LOH/allelic imbalance compared to tumors with normal heterozygosity (0.34 ± 0.09 and 0.74 ± 0.31, respectively). For SDHD, the mean relative expression was 2.9 times lower in tumors with LOH/allelic imbalance than in those without (0.29 ± 0.05 and 0.78 ± 0.24, respectively). Differences in means were significant for both genes, p = 0.0052 for SDHAF2 and p = 0.042 for SDHD, with the two-tailed Student's t test (Fig. 3) .
Immunohistochemistry SDHB protein expression intensity determined by immunohistochemistry was lower in the 6 analyzed PCCs (adrenal medulla) than in corresponding adrenal cortex (Fig. 4a, b) . However, no obvious correlation was observed between the perceived staining intensity and LOH and/or levels of mRNA expression.
Discussion
In the present study we have shown that loss of SDHAF2 and SDHD are frequent events in VHL-associated PCCs. More than 50 % of our tumor samples clearly displayed LOH at the SDHAF2 and SDHD regions. Another 7 and 20 % of the PCCs showed signs of LOH/allelic imbalance at the SDHAF2 and SDHD regions, respectively, but were inconclusive because the allele ratios were [0.7 but \0.8. A possible explanation for this could be heterogeneity of the tumors, which has recently been shown in PCCs [31] . For both SDHAF2 and SDHD, LOH was associated with a significantly (p \ 0.01 and p \ 0.05, respectively) decreased level of mRNA expression. Somatic mutations of SDHAF2 or SDHD were not detected in the investigated VHL-associated PCCs. Concerning SDHAF2, this is in agreement with earlier studies as SDHAF2 germline mutations have so far only been found in patients with PGLs but not PCCs [22, 32] . In contrast, mutations in SDHD [33] , SDHB [34] , SDHC [35] , and SDHA [36] were initially found in PGLs but later also in PCCs (SDHD [37, 38] , SDHB [34] , SDHC [11] , SDHA [39] ).
Promoter methylation of SDHAF2 or SDHD was not found in any of the investigated tumors. We did, however, detect promoter methylation of HIC1, a gene that has previously been found to be hypermethylated in VHLassociated PCCs [27] in all our investigated tumors (but not in blood), and we can thus conclude that the absence of promoter methylation is not due to complete absence of methylation in our samples. Presence of methylation at sites that we did not analyze, however, cannot be excluded.
If SDHAF2 or SDHD would function as tumor suppressor genes in these tumors, one would expect a second mechanism of gene inactivation in addition to LOH, in accordance with Knudsons two-hit model [40, 41] . Absence of mutations and promoter methylation may be in agreement with the putative maternal imprinting of SDHAF2 and SDHD [42] , but it may also be suggestive of other or additional important target genes on chromosome 11q. Therefore, despite the lack of both somatic mutations and methylation in SDHAF2 and SDHD, the significant downregulation of both genes on the mRNA level in tumors with LOH suggests a pathogenic role of these genes in VHL-associated PCCs. We therefore analyzed expression of the protein SDHB in our PCCs, as it is considered a universal marker for loss of any of the SDH subunits [23] . Actually, weak SDHB staining has been reported in VHLassociated PCCs [43] . Weak SDHB immunostaining of tumor tissue could be confirmed in the majority of the tumors investigated. However, we did not find any correlation between the mRNA levels of SDHAF2 and SDHD and the expression of SDHB, making it less likely that either gene plays a major role in the development of these tumors even though the number of tumors investigated with IHC was very limited in our study. In summary, we show a high frequency of allelic imbalance indicating LOH of both SDHAF2 and SDHD in VHL-associated PCCs that was associated with a significantly decreased expression of both genes on the mRNA level. Intensity of SDHB IHC staining, however, correlated with neither LOH nor altered mRNA levels. This and the absence of both mutations and/or methylation indicates that the studied genes SDHAF2 and SDHD are less likely to contribute a key genetic event for mitochondrial complex II change and subsequent formation of PCCs in carriers of VHL germline mutation. Other key genetic events on chromosome 11q remain to be looked for.
